Interpretation of kidney outcomes during combined SGLT2 inhibitor and GLP-1 receptor agonist therapy
Authors:
- Thijs T JanszTJThijs T Jansz
- Katherine G YoungKYKatherine G Young
- Martha M DinsdaleMDMartha M Dinsdale
- Pedro CardosoPCPedro Cardoso
- Richard A OramRORichard A Oram
- John M DennisJDJohn M Dennis
Open Access
- 12 August 2026
- journal article
- Published by Elsevier in The Lancet Primary Care
- Vol. 2 (8)
Abstract
No abstract availableFunding Information
- Medical Research Council
This publication has 4 references indexed in Scilit:
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2024
- Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 TrialsDiabetes Care, 2023
- Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines AgencyAmerican Journal of Kidney Diseases, 2020
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialThe Lancet, 2019